DK0941344T3 - Humaniserede anti-CD11a-antistoffer - Google Patents

Humaniserede anti-CD11a-antistoffer

Info

Publication number
DK0941344T3
DK0941344T3 DK97912841T DK97912841T DK0941344T3 DK 0941344 T3 DK0941344 T3 DK 0941344T3 DK 97912841 T DK97912841 T DK 97912841T DK 97912841 T DK97912841 T DK 97912841T DK 0941344 T3 DK0941344 T3 DK 0941344T3
Authority
DK
Denmark
Prior art keywords
humanized anti
cd11a antibodies
cd11a
antibodies
humanized
Prior art date
Application number
DK97912841T
Other languages
Danish (da)
English (en)
Inventor
Paula M Jardieu
Leonard G Presta
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of DK0941344T3 publication Critical patent/DK0941344T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2845—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta2-subunit-containing molecules, e.g. CD11, CD18
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DK97912841T 1996-11-27 1997-10-20 Humaniserede anti-CD11a-antistoffer DK0941344T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US75720596A 1996-11-27 1996-11-27

Publications (1)

Publication Number Publication Date
DK0941344T3 true DK0941344T3 (da) 2004-09-27

Family

ID=25046834

Family Applications (2)

Application Number Title Priority Date Filing Date
DK97912841T DK0941344T3 (da) 1996-11-27 1997-10-20 Humaniserede anti-CD11a-antistoffer
DK04004941.3T DK1516629T3 (da) 1996-11-27 1997-10-20 Humaniseret anti-CD-11a antibodies

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK04004941.3T DK1516629T3 (da) 1996-11-27 1997-10-20 Humaniseret anti-CD-11a antibodies

Country Status (17)

Country Link
EP (2) EP0941344B1 (oth)
JP (2) JP3778945B2 (oth)
KR (1) KR100532178B1 (oth)
AR (1) AR008919A1 (oth)
AT (1) ATE267257T1 (oth)
AU (1) AU731817C (oth)
CA (1) CA2272842C (oth)
DE (3) DE122004000047I2 (oth)
DK (2) DK0941344T3 (oth)
ES (1) ES2221045T3 (oth)
FR (1) FR04C0028I2 (oth)
IL (3) IL130143A0 (oth)
LU (1) LU91122I2 (oth)
NL (1) NL300163I2 (oth)
PT (1) PT941344E (oth)
WO (1) WO1998023761A1 (oth)
ZA (1) ZA979599B (oth)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7122636B1 (en) 1997-02-21 2006-10-17 Genentech, Inc. Antibody fragment-polymer conjugates and uses of same
EP1950300A3 (en) 1998-11-18 2011-03-23 Genentech, Inc. Antibody variants with higher binding affinity compared to parent antibodies
ES2301254T3 (es) 1998-11-18 2008-06-16 Genentech, Inc. Variantes de anticuerpos con una afinidad de union mayor en comparacion con los anticuerpos parentales.
US6582698B1 (en) 1999-03-19 2003-06-24 Genentech, Inc. Treatment method
ATE439145T1 (de) 1999-03-19 2009-08-15 Genentech Inc Behandlung von lfa-1 assozieerten krankheiten durch gesteigerte dosen von lfa-1 antagonist
ATE403437T1 (de) * 1999-12-14 2008-08-15 Genentech Inc Lfa-1 antagonisten und tnf-alpha antagonisten zur behandlung von rheumatoiden arthritis
US7575921B2 (en) 1999-12-30 2009-08-18 Vbi Technologies, L.L.C. Spore-like cells and uses thereof
US7560275B2 (en) 1999-12-30 2009-07-14 Vbi Technologies, L.L.C. Compositions and methods for generating skin
WO2001051084A1 (en) * 2000-01-14 2001-07-19 Genentech, Inc. Diagnosis and treatment of hepatic inflammatory disorders by inhibiting the binding of lfa-1 to icam-1
DE60140457D1 (de) * 2000-09-01 2009-12-24 Blood Res Center Veränderte, in gewünschter konformation stabilisierte polypeptide und verfahren zu deren herstellung
WO2002057428A1 (en) 2000-10-30 2002-07-25 University Of Massachusetts Isolation of spore-like cells from tissues exposed to extreme conditions
US6870034B2 (en) 2002-02-05 2005-03-22 Genentech, Inc. Protein purification
US20060234226A1 (en) 2002-04-26 2006-10-19 Fahner Robert L Non-affinity purification of proteins
DE60335552D1 (de) 2002-09-11 2011-02-10 Genentech Inc Neue zusammensetzung und verfahren zur behandlung von immunerkrankungen
US7388079B2 (en) * 2002-11-27 2008-06-17 The Regents Of The University Of California Delivery of pharmaceutical agents via the human insulin receptor
MXPA05011406A (es) * 2003-04-23 2005-12-12 Medarex Inc Anticuerpos humanizados para el receptor-1 de interferon alfa (ifnar-1).
DK1648940T3 (en) 2003-07-28 2016-08-15 Genentech Inc Reduction of leaching of protein A during protein A affinity chromatography
EP2168986A3 (en) 2004-02-19 2010-07-28 Genentech, Inc. CDR-repaired antibodies
JP5054385B2 (ja) 2004-02-19 2012-10-24 ダイアックス、コープ 立体配座特異的抗体
WO2005123777A2 (en) * 2004-06-09 2005-12-29 Genentech, Inc. Method of treating granuloma annulare or sarcoid
US7655229B2 (en) 2004-09-02 2010-02-02 Chan Andrew C Anti-FC-gamma RIIB receptor antibody and uses therefor
US7662926B2 (en) 2004-09-02 2010-02-16 Genentech, Inc. Anti-Fc-gamma receptor antibodies, bispecific variants and uses therefor
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
FR2902799B1 (fr) 2006-06-27 2012-10-26 Millipore Corp Procede et unite de preparation d'un echantillon pour l'analyse microbiologique d'un liquide
US8362217B2 (en) 2006-12-21 2013-01-29 Emd Millipore Corporation Purification of proteins
US8163886B2 (en) 2006-12-21 2012-04-24 Emd Millipore Corporation Purification of proteins
US8569464B2 (en) 2006-12-21 2013-10-29 Emd Millipore Corporation Purification of proteins
KR101431856B1 (ko) 2007-01-22 2014-08-27 제넨테크, 인크. 항체의 고분자전해질 침전 및 정제
HUE061746T2 (hu) 2007-07-09 2023-08-28 Genentech Inc Diszulfidkötés redukciójának megelõzése polipeptidek rekombináns elõállítása során
EP3441402A1 (en) 2007-10-30 2019-02-13 Genentech, Inc. Antibody purification by cation exchange chromatography
SI2279412T1 (sl) 2008-04-09 2017-10-30 Genentech, Inc., Novi sestavki in postopki za zdravljenje imunsko povezanih bolezni
WO2009151514A1 (en) 2008-06-11 2009-12-17 Millipore Corporation Stirred tank bioreactor
EP2145901B1 (en) 2008-07-18 2012-11-14 Technische Universität Braunschweig Recombinant anti-MUC1 antibodies
DK3604324T3 (da) 2008-08-14 2024-04-08 Genentech Inc Fremgangsmåder til at fjerne en kontaminant under anvendelse af ionbytningskromatografi med forskydning af iboende proteiner
CN102209554A (zh) 2008-09-10 2011-10-05 弗·哈夫曼-拉罗切有限公司 用于防止蛋白质氧化降解的组合物和方法
JP2012512244A (ja) 2008-12-16 2012-05-31 イー・エム・デイー・ミリポア・コーポレイシヨン タンパク質の精製
WO2010074953A1 (en) 2008-12-16 2010-07-01 Millipore Corporation Stirred tank reactor and method
US8435488B2 (en) 2009-02-27 2013-05-07 Genentech, Inc. Methods and compositions for protein labelling
AU2010282733B2 (en) 2009-08-11 2016-07-14 Genentech, Inc. Production of proteins in glutamine-free cell culture media
BR112012004697B8 (pt) 2009-09-01 2021-05-25 Genentech Inc método para purificar um polipeptídeo compreendendo uma região ch2/ch3
CA2780549C (en) 2009-11-12 2017-01-03 Vbi Technologies, L.L.C. Subpopulations of spore-like cells and uses thereof
EP2531592A1 (en) 2010-02-04 2012-12-12 Vivalis Fed-batch process using concentrated cell culture medium for the efficient production of biologics in eb66 cells
EP2550018B1 (en) 2010-03-22 2019-02-27 F.Hoffmann-La Roche Ag Compositions and methods useful for stabilizing protein-containing formulations
MX2012012743A (es) 2010-05-03 2012-11-23 Genentech Inc Composiciones y metodos utiles para reducir la viscosidad de formulaciones que contienen proteina.
DK2571903T3 (da) 2010-05-17 2019-11-04 Emd Millipore Corp Polymerer, der reagerer på stimuli, til oprensning af biomolekyler
BR112012030197A2 (pt) 2010-05-28 2015-09-29 Genentech Inc diminuição do nível de lactato e aumento da produção de poliptídeo por subregulação da expressão de lactato desidrogenase e piruvato desidrogenase cinase.
SI2585045T1 (sl) 2010-06-24 2019-11-29 Hoffmann La Roche Sestavki in postopki, ki vsebujejo alkilglikozide za stabilizacijo formulacij, ki vsebujejo beljakovine
MX2013001267A (es) 2010-08-13 2013-04-10 Genentech Inc ANTICUERPOS A IL-1ß E EIL-18 PARA TRATAMIENTO DE ENFERMEDAD.
WO2012030512A1 (en) 2010-09-03 2012-03-08 Percivia Llc. Flow-through protein purification process
WO2012088272A1 (en) * 2010-12-21 2012-06-28 Duke University Methods and compositions combining immunotherapy with monocyte activation
WO2012095514A1 (en) 2011-01-14 2012-07-19 Vivalis Recombinant protein production system
ES2697676T3 (es) 2011-12-22 2019-01-25 Hoffmann La Roche Cromatografía de membrana de intercambio iónico
US20140080180A1 (en) 2012-03-27 2014-03-20 Genentech, Inc. Harvest operations for recombinant proteins
JP6254581B2 (ja) 2012-05-18 2017-12-27 ジェネンテック， インコーポレイテッド 高濃度モノクローナル抗体製剤
WO2014100095A1 (en) 2012-12-19 2014-06-26 Genentech, Inc. Methods and compositions for radiohalogen protein labeling
SG10202008809RA (en) 2013-07-09 2020-10-29 Annexon Inc Anti-complement factor c1q antibodies and uses thereof
KR20250007687A (ko) 2013-07-16 2025-01-14 제넨테크, 인크. Pd-1 축 결합 길항제 및 tigit 억제제를 사용한 암을 치료하는 방법
SG11201700097WA (en) 2014-07-09 2017-02-27 Genentech Inc Ph adjustment to improve thaw recovery of cell banks
SG10202008810QA (en) 2014-11-05 2020-10-29 Annexon Inc Humanized anti-complement factor c1q antibodies and uses thereof
JP6861418B2 (ja) 2015-09-02 2021-04-28 イッサム リサーチ デベロップメント カンパニー オブ ザ ヘブリュー ユニバーシティー オブ エルサレム リミテッド ヒトｔ細胞免疫グロブリン及びｉｔｉｍドメイン（ｔｉｇｉｔ）に特異的な抗体
CN113912724B (zh) 2015-09-25 2025-03-14 豪夫迈·罗氏有限公司 抗tigit抗体和使用方法
BR112018010360A2 (en) 2015-11-24 2018-12-04 Annexon, Inc. anti-c1q complement factor fab fragments and uses thereof
WO2017172994A1 (en) 2016-03-29 2017-10-05 Geltor, Inc. Expression of proteins in gram-negative bacteria wherein the ratio of periplasmic volume to cytoplasmic volume is between 0.5:1 and 10:1
JP7553241B2 (ja) 2016-12-22 2024-09-18 ジェネンテック， インコーポレイテッド 凍結乾燥ポリペプチドの再構成時間を低減するための方法及び製剤
US11180541B2 (en) 2017-09-28 2021-11-23 Geltor, Inc. Recombinant collagen and elastin molecules and uses thereof
KR102870511B1 (ko) 2018-07-03 2025-10-15 브리스톨-마이어스 스큅 컴퍼니 재조합 단백질 생산 방법
KR20210074341A (ko) 2018-10-10 2021-06-21 베링거 인겔하임 인터내셔날 게엠베하 고밀도 생물 반응기 배양에서 막 기체 전달을 위한 방법
WO2020205716A1 (en) 2019-04-01 2020-10-08 Genentech, Inc. Compositions and methods for stabilizing protein-containing formulations
CN113993885B (zh) 2019-04-12 2025-04-25 格尔托公司 重组弹性蛋白及其生产
WO2021021973A1 (en) 2019-08-01 2021-02-04 Bristol-Myers Squibb Company Methods of improving protein productivity in fed-batch cell cultures
CN116194570A (zh) 2020-09-22 2023-05-30 百时美施贵宝公司 用于产生治疗性蛋白的方法
US20250115666A1 (en) 2021-08-05 2025-04-10 Bristol-Myers Squibb Company Cell culture methods for producing therapeutic proteins
WO2023049687A1 (en) 2021-09-21 2023-03-30 Bristol-Myers Squibb Company Methods of controlling the level of dissolved oxygen (do) in a solution comprising a recombinant protein in a storage container
WO2023114763A1 (en) 2021-12-13 2023-06-22 Annexon, Inc. Anti-complement factor c1q antibodies with single binding arms and uses thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ236792A (en) * 1990-01-19 1993-05-26 Merck & Co Inc Recombinant human anti-cd18 antibody, murine 1b4 heavy or light chain variable region, dna, vectors, mammalian host and pharmaceutical compositions
US6096871A (en) * 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life

Also Published As

Publication number Publication date
EP0941344B1 (en) 2004-05-19
FR04C0028I2 (oth) 2007-10-26
AU731817B2 (en) 2001-04-05
IL130143A (en) 2006-08-01
CA2272842A1 (en) 1998-06-04
JP4309383B2 (ja) 2009-08-05
PT941344E (pt) 2004-10-29
KR100532178B1 (ko) 2005-12-01
AU4992997A (en) 1998-06-22
JP2001505425A (ja) 2001-04-24
LU91122I2 (fr) 2005-01-10
JP2006036779A (ja) 2006-02-09
AU731817C (en) 2001-11-01
IL175583A0 (en) 2006-09-05
DE122004000047I2 (de) 2006-06-14
DE69729209D1 (de) 2004-06-24
EP1516629A3 (en) 2006-09-27
NL300163I2 (nl) 2005-07-01
ZA979599B (en) 1999-04-28
KR20000069147A (ko) 2000-11-25
WO1998023761A1 (en) 1998-06-04
JP3778945B2 (ja) 2006-05-24
IL130143A0 (en) 2000-06-01
NL300163I1 (nl) 2005-01-03
ES2221045T3 (es) 2004-12-16
DE69729209T2 (de) 2005-05-19
EP0941344A1 (en) 1999-09-15
ATE267257T1 (de) 2004-06-15
CA2272842C (en) 2012-05-15
DE122004000047I1 (de) 2005-04-21
DK1516629T3 (da) 2013-06-03
EP1516629B1 (en) 2013-04-03
FR04C0028I1 (oth) 2005-02-11
AR008919A1 (es) 2000-02-23
EP1516629A2 (en) 2005-03-23

Similar Documents

Publication Publication Date Title
DK0941344T3 (da) Humaniserede anti-CD11a-antistoffer
CY2005008I1 (el) Αντισωματα αντι - vegf
NO955167D0 (no) Monoklonalt anti-
DK0837927T3 (da) Anti-CD80-antistoffer
NO985464D0 (no) Konsentrert antistoffpreparat
DE69920897D1 (de) Monoklonale antikörper mit verringerter immunisierungsfähigkeit
DK145493D0 (da) Antistof
FI964845L (fi) CD44v6:n vastaiset monoklonaaliset vasta-aineet
FI951568A7 (fi) Immobilisoitu beta-mannaasi
DE69625078D1 (de) Analysator
DE69609663D1 (de) Automatische Analysevorrichtung
DE69738312D1 (de) Hepatitis b monoklonale antikörper
DE59606218D1 (de) Rohrleitung
NO981454L (no) Anti-FAS-antistoffer
DE69624334D1 (de) Fixiervorrichtung
KR970025982U (ko) 콘센트
BR9609863A (pt) Fecho
DE69618534D1 (de) Fixiervorrichtung
KR960036248U (ko) 도마
BR9709080A (pt) Anticorpo monoclonal anti-MP52 humano
KR960035664U (ko) 콘센트
KR970003345U (ko) 콘센트
KR970018128U (ko) 토건용 축조부재
KR970020763U (ko) 도마
ITMI950511A0 (it) Fotodensitometro parallelo perfezionato